Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 7/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25604862 | 1.00 | CHRM4 (0.39) | CHRM4CHRM1CHRM2JAK3BTK | |
| SCHEMBL25604813 | 0.90 | CHRM4 (0.39) | CHRM4CHRM1CHRM2JAK3BTK | |
| SCHEMBL25604828 | 0.90 | CHRM4 (0.39) | CHRM4CHRM1CHRM2JAK3BTK | |
| SCHEMBL25604866 | 0.87 | CHRM4 (0.38) | CHRM4CHRM1CHRM2JAK3BTK | |
| SCHEMBL24838522 | 0.87 | HRH3 (0.37) | CHRM4CHRM1CHRM2JAK3BTK | |
| SCHEMBL25604884 | 0.87 | HRH3 (0.37) | CHRM4CHRM1CHRM2JAK3BTK | |
| SCHEMBL26157132 | 0.84 | SLC18A3 (0.36) | JAK3BTKHSD11B1TLR9TLR8 | |
| SCHEMBL25605226 | 0.84 | HRH3 (0.45) | HRH3HSD11B1 | |
| SCHEMBL25654091 | 0.83 | CHRM4 (0.50) | CHRM4CHRM1CHRM2HRH3CHRM5 | |
| SCHEMBL24838652 | 0.78 | CHRM4 (0.37) | CHRM4CHRM1CHRM2JAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CHRM4 4484/4885CHRM1 4634/4885CHRM2 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.